Strona główna
  • Zamawiaj do paczkomatu
  • Płać wygodnie
  • Obniżka
Parkinson's Disease: Current and Future Therapeutics and Clinical Trials

Parkinson's Disease: Current and Future Therapeutics and Clinical Trials

9781107053861
598,44 zł
538,59 zł Zniżka 59,85 zł Brutto
Najniższa cena w okresie 30 dni przed promocją: 538,59 zł
Ilość
Od 4 do 6 tygodni

  Dostawa

Wybierz Paczkomat Inpost, Orlen Paczkę, DPD, Pocztę, email (dla ebooków). Kliknij po więcej

  Płatność

Zapłać szybkim przelewem, kartą płatniczą lub za pobraniem. Kliknij po więcej szczegółów

  Zwroty

Jeżeli jesteś konsumentem możesz zwrócić towar w ciągu 14 dni*. Kliknij po więcej szczegółów

Opis
Parkinsons disease is no longer considered only a motor disorder. It has become evident that the pathological changes are broad, the progression seems to follow a pattern suggesting transynaptic transmission via templation of proteins in a prion-like fashion, and that these pathological changes usually antedate the motor symptoms by decades. This book emphasizes treatment options for Parkinsons disease, critically assessing pharmacologic and surgical interventions for all aspects of the disease. Evidence from randomized controlled clinical trials is highlighted to develop practical recommendations for clinical practice. Lessons learnt from clinical trials - and controversies and future challenges - are all addressed. Readers will find the necessary clinical and scientific foundations for the understanding of the disease, the underpinnings of the pathological processes, the identification of disease biomarkers, and the basis for solid therapeutics. Chapters are authored by an international team of specialists who bring their expertise to improving the management of this disease.
Szczegóły produktu
Cambridge University Press
66186
9781107053861
9781107053861

Opis

Rok wydania
2016
Numer wydania
1
Oprawa
twarda
Liczba stron
384
Wymiary (mm)
194.00 x 253.00
Waga (g)
990
  • Part I. The Pharmacological Basis for Parkinsons Disease Treatment:: 1. The pharmacological basis of Parkinsons disease therapy:: an overview; 2. Anticholinergic agents in the management of Parkinsons disease; 3. Amantadine and antiglutamatergic drugs in the management of Parkinsons disease; 4. Monoamine oxidase inhibitors in the management of Parkinsons disease; 5. Oral dopamine agonists in the anagement of Parkinsons disease; 6. Subcutaneous, intranasal and transdermal dopamine agonists in the management of Parkinsons disease; 7. Oral and infusion levodopa therapy in the management of Parkinsons disease; 8. Catechol-O-methyltransferase inhibitors in the management of Parkinsons disease; 9. Experimental pharmacological agents in the management of Parkinsons disease; Part II. Management of Non-Motor Symptoms of Parkinsons Disease:: 10. Management of autonomic dysfunction in Parkinsons disease; 11. Management of cognitive impairment in Parkinsons disease; 12. A neurobehavioralist approach to the management of cognitive impairment in Parkinsons disease; 13. Management of disease-related behavioral disturbances in Parkinsons disease; 14. Management of treatment-related behavioral disturbances in Parkinsons disease; 15. Management of sleep disorders in Parkinsons disease; 16. Management of pain and euromuscular complications in Parkinsons disease; Part III. Surgical Management of Parkinsons Disease:: 17. Thalamotomy, pallidotomy and subthalamotomy in the management of Parkinsons disease; 18. Deep brain stimulation of the globus pallidus internus in the management of Parkinsons disease; 19. Deep brain stimulation of the subthalamic nucleus in the management of Parkinsons disease; 20. Deep brain stimulation of the thalamic ventral intermediate nucleus in the management of Parkinsons disease; 21. Emerging targets and other stimulation-related procedures in the management of Parkinsons disease; Part IV. Clinical Trials in Parkinsons Disease:: Lessons, Controversies and Challenges:: 22. Rating scales and clinical outcome measures in the evaluation of patients with Parkinsons disease; 23. Functional imaging markers as outcome measures in clinical trials for Parkinsons disease; 24. Cerebrospinal fluid and blood biomarkers as outcome measures in clinical trials for Parkinsons disease; 25. Lessons learned:: neuroprotective trials in Parkinsons disease; 26. Lessons learned:: symptomatic trials in early Parkinsons disease; 27. Controversy:: GPi vs STN deep brain stimulation in the management of Parkinsons disease; 28. Controversy:: ablative surgery vs deep brain stimulation in the management of Parkinsons disease; 29. Controversy:: mid-stage vs advanced stage deep brain stimulation in the management of Parkinsons disease; 30. Lessons and challenges of trials for cognitive and behavioral complications of Parkinsons disease; 31. Lessons and challenges of trials for other non-motor complications of Parkinsons disease; 32. Lessons and challenges of trials involving ancillary therapies for the management of Parkinsons disease; Index.
Komentarze (0)

  • Często kupowane razem

    Brak dostępnych produktów